> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Arthritis Drugs Panel to Review Eli Lilly NDA
- URL: https://www.fdaweb.com/arthritis-drugs-panel-to-review-eli-lilly-nda/
- Published: 2018-03-16T12:00:00.000Z
- Updated: 2026-09-14T23:53:46.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141000

*Federal Register* notice: FDA has announced a 4/23 g Arthritis Advisory Committee meeting. Panel members are scheduled to discuss an Eli Lilly NDA for baricitinib tablets, indicated for treating adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. The discussion will efficacy, safety, including the risk of thromboembolic adverse events, dose selection, and overall risk benefit considerations. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-03-16/pdf/2018-05386.pdf?ref=fdaweb.com).